KEVEYIS
LOE Approachingdichlorphenamide
NDAORALTABLET
Approved
Jul 1958
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
5/8 — Partial
KEVEYIS (dichlorphenamide) is carbonic anhydrase inhibitors [moa]. Approved for primary hyperkalemic periodic paralysis, primary hypokalemic periodic paralysis, related variants (). First approved in 1958.
Drug data last refreshed 10m ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
KEVEYIS (dichlorphenamide) is an oral carbonic anhydrase inhibitor approved in 1958 for treatment of primary hyperkalemic and hypokalemic periodic paralysis and related variants. It works by inhibiting carbonic anhydrase, reducing ion channel dysfunction that causes episodic muscle paralysis attacks. This rare disease therapy addresses an ultra-niche patient population with limited treatment options.
$21MPart D
LOE ApproachingStable
Ultra-niche rare disease with stable but modest commercial footprint approaching LOE; brand team likely small and maintenance-focused.
Mechanism of Action
Carbonic Anhydrase Inhibitors
Pharmacologic Class:
Carbonic Anhydrase Inhibitor
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.